Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerry Taylor

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Journal of Immunological Methods|August 8, 2002
Monitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: a platform for cancer immunotherapyJ Alejandro López, Georgina Crosbie, Cathryn Kelly, et al.
Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Leukemia & Lymphoma|February 26, 2008
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapseSteven Lane, Russell Saal, Peter Mollee, et al.
Australian and New Zealand Journal of Public Health|May 30, 2019
Feasibility and acceptability of opportunistic screening to detect atrial fibrillation in Aboriginal adultsRona Macniven, Josephine Gwynn, Hiroko Fujimoto, et al.
Forensic Science International|March 14, 2026
Case series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigationsMunchelou M Gomonit, Sara E Walton, Donna M Papsun, et al.
Haematologica|September 30, 2021
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Heart, Lung & Circulation|August 19, 2020
Atrial Fibrillation in Indigenous Australians: A Multisite Screening Study Using a Single-Lead ECG Device in Aboriginal Primary Health SettingsJosephine Gwynn, Kylie Gwynne, Rhys Rodrigues, et al.
Haematologica|December 15, 2018
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemiaMelita Kenealy, Mark Hertzberg, Warwick Benson, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Journal of Immunological Methods|August 8, 2002
Monitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: a platform for cancer immunotherapyJ Alejandro López, Georgina Crosbie, Cathryn Kelly, et al.
Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Leukemia & Lymphoma|February 26, 2008
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapseSteven Lane, Russell Saal, Peter Mollee, et al.
Australian and New Zealand Journal of Public Health|May 30, 2019
Feasibility and acceptability of opportunistic screening to detect atrial fibrillation in Aboriginal adultsRona Macniven, Josephine Gwynn, Hiroko Fujimoto, et al.
Forensic Science International|March 14, 2026
Case series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigationsMunchelou M Gomonit, Sara E Walton, Donna M Papsun, et al.
Haematologica|September 30, 2021
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Heart, Lung & Circulation|August 19, 2020
Atrial Fibrillation in Indigenous Australians: A Multisite Screening Study Using a Single-Lead ECG Device in Aboriginal Primary Health SettingsJosephine Gwynn, Kylie Gwynne, Rhys Rodrigues, et al.
Haematologica|December 15, 2018
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemiaMelita Kenealy, Mark Hertzberg, Warwick Benson, et al.
Pageof 8